What is the Cartalax Blend and what does each component do?

The Cartalax Blend (P-067) is an 80 MG lyophilized four-component preparation: Cartalax (Ala-Glu-Asp, 20 MG) — a bioregulatory tripeptide proposed to upregulate collagen type II and aggrecan in chondrocytes; BPC-157 (GEPPPGKPADDAGLV, 20 MG) — angiogenic and cytoprotective via VEGFR2/NO/FAK-paxillin; TB-500 (LKKTETQ, 20 MG) — G-actin sequestration promoting cell migration; KPV (Lys-Pro-Val, 20 MG) — intracellular NF-κB and MAPK inhibition via PepT1.

What are the molecular identifiers for each Cartalax Blend component?

Cartalax: Ala-Glu-Asp; MW ~333.3 g/mol. BPC-157: CAS 137525-51-0; MW 1419.53 g/mol; sequence GEPPPGKPADDAGLV. TB-500: CAS 885340-08-9; MW 831.96 g/mol (LKKTETQ fragment). KPV: CAS 6057-43-8; MW ~342.4 g/mol; Lys-Pro-Val.

What preclinical evidence supports Cartalax's role in cartilage biology?

Cartalax (Ala-Glu-Asp) is a bioregulatory peptide from the Khavinson program. Preclinical chondrocyte and rodent joint studies report 20–40% increases in collagen type II and aggrecan transcriptional markers versus controls, alongside MMP-1 and MMP-13 suppression. Histological assessments show modestly improved cartilage integrity in surgically induced joint instability models. No Phase II/III human trials have been completed; the compound remains investigational.

How does KPV's mechanism interact with the other Cartalax Blend components in inflamed tissue?

KPV's intracellular NF-κB inhibition suppresses the cytokine milieu (TNF-α, IL-1β, IL-6) that drives chondrocyte catabolism and impairs tissue repair. This anti-inflammatory environment supports Cartalax's anabolic gene regulation, BPC-157's angiogenic scaffolding, and TB-500's cell migration activities — all of which are attenuated in high-cytokine states. PepT1-mediated KPV uptake is enhanced in inflamed gut and wound tissue, creating a natural self-targeting effect.

How should Cartalax Blend be stored and reconstituted?

Store lyophilized blend at −20 °C, protected from light and moisture. Reconstitute by adding bacteriostatic water slowly down the inner wall of the vial and gently swirling — do not vortex. After reconstitution, store at 2–8 °C for up to 28 days (USP multi-dose container guidance). Avoid freeze-thaw cycling once reconstituted.

BPC-157, Cartalax, KPV, TB-500 Blend

Name: Cartalax Blend
Brand: Kaiser BioMed
SKU: P-067
Price: 149.00 USD
Availability: InStock

Description

Summary Abstract

Cartalax Blend (P-067; Cartalax 20 MG + BPC-157 20 MG + TB-500 20 MG + KPV 20 MG; 80 MG total lyophilized blend) is a four-component formulation designed for connective tissue, cartilage, and wound repair research. Cartalax (Ala-Glu-Asp) is a chondrocyte-targeting bioregulatory tripeptide proposed to upregulate collagen type II and aggrecan transcription via epigenetic modulation, derived from the Khavinson bioregulator program. BPC-157 (Body Protection Compound-157; GEPPPGKPADDAGLV) contributes pro-angiogenic and cytoprotective activity via the VEGFR2/NO/FAK-paxillin axis. TB-500 (thymosin β4 fragment LKKTETQ) provides actin-sequestration–dependent cell migration and tissue remodeling support. KPV (Lys-Pro-Val; α-MSH C-terminal tripeptide) delivers targeted NF-κB inhibition and MAPK pathway suppression via PepT1-mediated intracellular entry in inflamed tissue. Together, the four components address the cartilage catabolic cascade, tissue vascularization, cytoskeletal remodeling, and chronic inflammatory signaling in a single lyophilized preparation.

Clinical Indications

Each component targets a distinct layer of connective tissue pathology, with collective relevance to the following research contexts:

Cartilage Matrix Support: Cartalax upregulates collagen type II (COL2A1) and aggrecan (ACAN) gene expression in chondrocytes, addressing the anabolic deficit in degenerative joint research while suppressing MMP-1/MMP-13 catabolic enzymes.
Tendon, Ligament, and Wound Repair: BPC-157 and TB-500 both demonstrate accelerated repair in tendon transection and wound closure models through complementary angiogenic and actin-remodeling pathways.
Mucosal and Gastrointestinal Inflammation: KPV’s PepT1-mediated gut delivery and BPC-157’s gastric cytoprotective properties combine for multi-targeted mucosal protection in IBD and colitis research models.
Systemic and Dermal Inflammation: KPV’s NF-κB inhibition and TB-500’s anti-inflammatory activity support investigation of wound-associated and systemic inflammatory states where multiple pathways contribute to tissue damage.

Contraindications

Active Malignancy: Pro-angiogenic components (BPC-157 VEGFR2/NO axis; TB-500 VEGF-dependent signaling) carry a theoretical risk of supporting tumor neovascularization; use in oncological contexts requires consideration of tumor angiogenesis potential.
Broad Immunosuppressive States: KPV’s NF-κB inhibition may attenuate physiological inflammatory responses required for pathogen clearance; use in severely immunocompromised subjects requires assessment.
Pregnancy and Lactation: No reproductive safety data exist for any component; use is not established in pregnant or lactating individuals.
Multi-Peptide Hypersensitivity: Blended formulations increase hypersensitivity surface area; documented sensitivity to any constituent peptide represents a contraindication.

Mechanism of Action (MOA)

Each component engages a distinct molecular pathway, producing complementary and synergistic effects on connective tissue repair and inflammation resolution:

Cartalax — Chondrocyte Epigenetic Gene Regulation

Cartalax (Ala-Glu-Asp) is a bioregulatory tripeptide hypothesized to translocate to the nucleus in chondrocytes, where it interacts with chromatin regulatory elements to upregulate transcription of collagen type II alpha-1 (COL2A1) and aggrecan (ACAN) — the primary structural proteins of articular cartilage extracellular matrix. Preclinical evidence also indicates downregulation of matrix metalloproteinase (MMP)-1 and MMP-13 catabolic enzymes, shifting the anabolic/catabolic balance toward matrix preservation.

BPC-157 — VEGFR2/NO/FAK-Paxillin Angiogenesis and Cytoprotection

BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and modulates the nitric oxide (NO) system bidirectionally, promoting angiogenesis and vascular remodeling in ischemic and injured tissue. Activation of the FAK-paxillin integrin pathway enhances fibroblast and tenocyte migration, accelerating extracellular matrix deposition and tensile strength recovery in tendon, ligament, and mucosal injury models.

TB-500 — G-Actin Sequestration and Cytoskeletal Remodeling

TB-500 (thymosin β4 fragment, LKKTETQ) maintains the intracellular G-actin monomer pool through 1:1 stoichiometric sequestration of unpolymerized actin, modulating the G-actin/F-actin ratio to promote lamellipodia formation and directed cell migration. Downstream VEGF-dependent paracrine signaling and PINCH–ILK–Akt pathway engagement support endothelial recruitment and anti-apoptotic responses in cardiac and skeletal muscle ischemia models.

KPV — PepT1-Mediated Intracellular NF-κB and MAPK Inhibition

KPV (Lys-Pro-Val) enters epithelial and immune cells via the peptide transporter PepT1 (SLC15A1), bypassing cell-surface receptor engagement entirely. Intracellularly, KPV competes with importin-α for binding at armadillo domains 7 and 8 of NF-κB p65/RelA, blocking nuclear translocation and suppressing TNF-α, IL-1β, IL-6, and IL-8 transcription. Parallel ERK/p38 MAPK inhibition further broadens the anti-inflammatory profile across cell types including keratinocytes, macrophages, and intestinal epithelial cells.

Key Features & Specifications

Four mechanistically complementary components address cartilage repair, tissue vascularization, cytoskeletal remodeling, and NF-κB–mediated inflammation in a single 80 MG preparation:

Cartalax (Ala-Glu-Asp) — Chondrocyte Epigenetic Cartilage Support

BPC-157 (GEPPPGKPADDAGLV) — VEGFR2/NO Angiogenesis & Cytoprotection

TB-500 (LKKTETQ Fragment) — G-Actin Sequestration & Cell Migration

KPV (Lys-Pro-Val) — NF-κB/MAPK Dual-Pathway Anti-Inflammatory

80 MG Total Blend — 20 MG Each Component; Single Lyophilized Vial

Internal Links to Individual Component Product Pages

Chemical Analysis

Property	Specification Reference Data
Component 1 — Cartalax	Sequence: Ala-Glu-Asp (AED tripeptide bioregulator); MW: ~333.3 g/mol; Tissue target: chondrocytes
Component 2 — BPC-157	Sequence: GEPPPGKPADDAGLV; CAS: 137525-51-0; MW: 1419.53 g/mol; Origin: gastric juice protein fragment
Component 3 — TB-500	Sequence: LKKTETQ (thymosin β4 fragment, residues 17–23); CAS: 885340-08-9; MW: 831.96 g/mol; Full Tβ4: 43 AA, MW 4963.5 g/mol
Component 4 — KPV	Sequence: Lys-Pro-Val; CAS: 6057-43-8; MW: ~342.4 g/mol; Parent: α-MSH C-terminus (residues 11–13)
Blend Composition	Cartalax 20 MG + BPC-157 20 MG + TB-500 20 MG + KPV 20 MG = 80 MG total lyophilized
Form / Variation	80 MG Lyophilized Blend (P-067) — single SKU; reconstitute with bacteriostatic water
Synonyms	Cartalax Blend; Connective Tissue Quad Blend; KBM Cartalax Combo

Storage, Safety, and Handling

Storage Protocol

Store lyophilized blend at −20 °C, shielded from light and moisture. Upon reconstitution with bacteriostatic water, the solution is stable at 2–8 °C for up to 28 days per USP <797> multi-dose container guidance; avoid repeated freeze-thaw cycling after reconstitution. The shortest-stability component in the blend governs the practical beyond-use date.

Handling & Compliance

Handle under standard laboratory precautions (nitrile gloves, safety glasses) using aseptic technique throughout reconstitution. Each component carries its own pharmacological activity; personnel should be familiar with the mechanisms and safety profiles of all four constituents before use. TB-500 (thymosin β4 and fragments) is classified as a prohibited substance under the World Anti-Doping Agency (WADA) S2 Peptide Hormone category.